Please login to the form below

Not currently logged in
Email:
Password:

Investigation into Merck & Co drug

The US Food and Drugs Administration announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The US Food and Drugs Administration (FDA) announced on March 27 that it has launched an investigation into the drug Singulair, which is manufactured by Merck & Co.

The FDA has said that is investigation a possible association between the use of the drug and suicidal behaviour and thinking after analysing the most up-to-date information pertaining to the use of Singulair.

Singulair is a leukotriene receptor antagonist indicated for the treatment of patients with asthma and symptoms of allergic rhinitis and to prevent exercise-induced asthma.

The FDA said: "Until further information is available, healthcare professionals and caregivers should monitor patients taking Singulair for suicidality (suicidal thinking and behaviour) and changes in behaviour and mood."

The FDA did, however, caution that "patients should not stop taking Singulair before talking to their doctor if they have questions about this new information."

Evaluation of the date and the possible link between Singulair and suicidal behaviour and thinking may take up to nine months at which point the FDA's findings will be made available to the public.

27th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics